CETP and Stroke: In a 2014 study by Keene et al., neither CETP inhibitors, nor niacin or fibrates, all of which effectively raise HDL-C levels, reduced all-cause mortality, coronary heart disease mortality, MI, or stroke in patients treated with statins [49], the mainstay of lipid-lowering therapy.